Literature DB >> 23430165

Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin.

R Dersch, O Stich, K Goller, S Meckel, F Dechent, S Doostkam, C Weiller, J Bardutzky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23430165     DOI： 10.1007/s00415-013-6866-6

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  7 in total

1.  Gemcitabine-induced posterior reversible encephalopathy syndrome: a case report.

Authors:  Pasquale Cioffi; Lucio Laudadio; Antonio Nuzzo; Maurizio Belfiglio; Fabio Petrelli; Iolanda Grappasonni
Journal:  J Oncol Pharm Pract       Date:  2011-11-07       Impact factor: 1.809

2.  Neuropathological correlates of reversible posterior leukoencephalopathy.

Authors:  David Schiff; Maria-Beatriz Lopes
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

Review 4.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 5.  Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.

Authors:  R C S Seet; A A Rabinstein
Journal:  QJM       Date:  2011-08-24

Review 6.  Bevacizumab-induced hypertension: pathogenesis and management.

Authors:  Kostas N Syrigos; Eleni Karapanagiotou; Paraskevi Boura; Christian Manegold; Kevin Harrington
Journal:  BioDrugs       Date:  2011-06-01       Impact factor: 5.807

7.  The effect of bevacizumab (Avastin) on neuroimaging of brain metastases.

Authors:  Marlon S Mathews; Mark E Linskey; Anton N Hasso; John P Fruehauf
Journal:  Surg Neurol       Date:  2008-02-08
  7 in total
  8 in total

1.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

2.  One and the same.

Authors:  Ryan T Fitzgerald
Journal:  Rev Obstet Gynecol       Date:  2013

3.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

4.  Malignant Posterior Reversible Encephalopathy Syndrome-An Exacting Challenge for Neurocritical Care Physicians.

Authors:  Shahvaiz Magsi; Atif Zafar
Journal:  Neurohospitalist       Date:  2017-02-08

5.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21

6.  Posterior reversible encephalopathy syndrome induced by food poisoning in a pediatric patient: a case report.

Authors:  Xue-Mei Wu; Guang-Liang Wang; Chang-Gui Kou; Jiang-Tao Wang; Jian-Min Liang; Ya-Qin Yu
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

7.  A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.

Authors:  Hannah Cherniawsky; Neesha Merchant; Micheal Sawyer; Maria Ho
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

8.  Delayed Posterior Reversible Leukoencephalopathy Syndrome Triggered by FLOT Chemotherapy.

Authors:  Jordi Gandini; Mario Manto; Nicolas Charette
Journal:  Front Neurol       Date:  2020-01-30       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.